Alvotech (NASDAQ:ALVO) Q4 2022 Results Conference Call March 2, 2023 8:00 AM ET
Company Participants
Benedikt Stefansson - Director of Investor Relations
Robert Wessman - Chairman and CEO
Anil Okay - Chief Commercial Officer
Hafrun Fridriksdottir - Chief Operating Officer
Joel Morales - Chief Financial Officer
Conference Call Participants
Thibault Boutherin - Morgan Stanley
Niall Alexander - Deutsche Bank
Andrew Baum - Citi
Benedikt Stefansson
Thank you, and good morning or afternoon to everyone joining this call today.
Yesterday evening, the company issued a press release that can be found on our website, investors.alvotech.com, under News and Events in the Events and Presentations section. The press release reports financial results for fiscal year 2022 and provides a business update.
Additionally, presentation slides that cover our call today will be posted on our website at investors.alvotech.com. Please look under News and Events for the Events and Presentations section.
Our presentation materials and some of our statements that we make today may include forward-looking statements. These statements do not ensure future performance, and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ending December 31, 2022. These risks and uncertainties could cause actual results to differ materially from forward-looking statements that are made.
With me on today's call are Robert Wessman, Chairman and CEO of Alvotech; Hafrun Fridriksdottir, Chief Operating Officer; Joel Morales, Chief Financial Officer; Anil Okay, Chief Commercial Officer; and Ming Li, Chief Strategy Officer.
With that, I would like to turn the call over to Robert Wessman.
Robert Wessman
Thank you, Benedikt, and welcome, everyone, to our fourth quarter and full year 2022 update call.
As you know, I have recently been appointed as a Chief Executive Officer for Alvotech. I see this as a seamless extension of my role as Executive Chairman. I'm excited to take on this new challenge, and continue to drive Alvotech's growth and success in the global biosimilar markets.
I'm also thrilled to welcome Hafrun Fridriksdottir to Alvotech as our Chief Operating Officer. Hafrun brings a wealth of experience in the pharmaceutical industry, most recently at Teva Pharmaceuticals.
Before we move to our business update, I want again to reinforce Alvotech core competence. Alvotech is a pure-play biosimilar platform. I believe that we have the infrastructure, the personnel, the processes and the dedication it takes to be successful in the biosimilar space.